Additional evidence for efficacy from dual PI3K/mTOR inhibition in B-ALL stems from experiments in Ph+-B-ALL with BEZ235, a dual pan-PI3K/mTORC1/mTORC2 inhibitor. This evidence concerns the gene PIK3CD and acute lymphoblastic leukemia.